10-Q: Cardiff Oncology Reports Third Quarter 2024 Financial Results and Provides Clinical Program Update

Cardiff Oncology's Q3 2024 report details financial results, clinical trial progress, and a focus on their lead drug candidate, onvansertib.

Summary

• Cardiff Oncology reported a net loss of $11.86 million for the three months ended September 30, 2024, and a net loss of $33.66 million for the nine months ended September 30, 2024.
• The company's cash, cash equivalents, and short-term investments totaled $57.7 million as of September 30, 2024.
• Royalty revenues were $0.165 million for the quarter and $0.532 million for the nine-month period.
• Research and development expenses were $9.64 million for the quarter and $27.14 million for the nine-month period, primarily due to clinical program costs.
• Selling, general, and administrative expenses were $3.13 million for the quarter and $9.47 million for the nine-month period.
• The company believes it has sufficient cash to meet its funding requirements for at least the next 12 months.
• Cardiff Oncology is advancing its clinical programs for onvansertib, including trials in RAS-mutated metastatic colorectal cancer (mCRC), metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple-negative breast cancer (TNBC).

Sentiment

Score: 7

Explanation: The document presents a mix of positive clinical trial results and financial challenges. The clinical data for onvansertib is promising, particularly in specific patient subgroups, but the company's ongoing losses and need for additional capital raise some concerns. The overall sentiment is cautiously optimistic.

Positives

• Onvansertib shows promising results in clinical trials, particularly in bevacizumab-naive patients with mCRC.
• The company has a strong cash position of $57.7 million, which is expected to fund operations for at least the next 12 months.
• The company is actively advancing multiple clinical programs across various cancer indications.
• The company has received FDA approval for NALIRIFOX as a first-line treatment option for mPDAC, which will be incorporated into a new investigator-initiated trial.
• The company has published data from the Phase 1b portion of the TROV-054 trial in Clinical Cancer Research and data from the Phase 2 portion in Clinical Oncology.

Negatives

• The company has incurred significant net losses since its inception and has negative operating cash flows.
• The company is dependent on raising additional capital to fund its operations and clinical programs.
• The company's ONSEMBLE trial showed no objective responses in bevacizumab-exposed patients.
• The company has experienced a decrease in cash and cash equivalents from $21.655 million at the end of 2023 to $13.038 million at the end of Q3 2024.

Risks

• The company's drug development efforts are in their early stages, and there are many uncertainties involved in bringing new drug candidates to market.
• The company may not be able to raise additional capital on acceptable terms, or at all.
• The company's clinical trials may not be successful, and its drug candidates may not receive regulatory approval.
• The company faces competition from other biotechnology companies developing cancer therapies.
• The company's financial performance may be affected by various factors, including changes in the regulatory environment, economic conditions, and market trends.

Future Outlook

The company expects to release initial data from the CRDF-004 trial in the fourth quarter of 2024 and believes its current capital resources are sufficient to fund operations into the first quarter of 2026. The company anticipates continuing to incur losses and will require additional capital to advance its clinical programs.

Management Comments

• Management believes the company has sufficient cash to meet its funding requirements for at least the next 12 months.
• Management is focused on advancing the clinical development of onvansertib across multiple cancer indications.
• Management is planning to support a new investigator-initiated mPDAC Phase 2 trial of onvansertib in combination with first-line SoC NALIRIFOX.

Industry Context

Cardiff Oncology is operating in the competitive biotechnology sector, focusing on oncology therapeutics. The company's approach of combining onvansertib with standard-of-care treatments aligns with the industry trend of exploring combination therapies to improve patient outcomes. The company's focus on specific tumor vulnerabilities and biomarker assays is also consistent with the industry's move towards personalized medicine.

Comparison to Industry Standards

• The objective response rate (ORR) of 29% in the TROV-054 trial for second-line KRAS-mutated mCRC is higher than historical controls of 5-13% for similar patient populations using different drug combinations.
• The median progression-free survival (mPFS) of 9.3 months in the TROV-054 trial is also longer than the historical control of 4.5-6.7 months.
• The 73% ORR and 15-month mPFS in bevacizumab-naive patients in the TROV-054 trial is significantly higher than the results seen in similar trials with other treatments.
• The 19% ORR and 5.0-month mPFS in the CRDF-001 trial for mPDAC is also higher than the historical control of 7.7% ORR and 3.1-month mPFS in the second-line setting.
• These results suggest that onvansertib may offer a more effective treatment option compared to existing therapies in these specific patient populations. Companies such as Amgen, with their KRAS inhibitor Lumakras, and Mirati Therapeutics, with their KRAS inhibitor Krazati, are also targeting similar patient populations, but with different mechanisms of action. Cardiff's approach of combining onvansertib with standard-of-care treatments may offer a unique advantage.

Legal Proceedings

• A purported stockholder class action was mooted on June 20, 2024, and dismissed on June 26, 2024, with the company agreeing to pay $400,000 in attorneys fees and expenses.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity offerings.
• Employees are impacted by stock-based compensation and potential changes in the company's financial stability.
• Patients with cancer may benefit from the development of new therapies like onvansertib.
• The company's suppliers and creditors are impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• The company plans to release initial data from the CRDF-004 trial in the fourth quarter of 2024.
• The company plans to initiate CRDF-005, a Phase 3, randomized trial with registrational intent, contingent upon the results of CRDF-004.
• The company is planning to support a new investigator-initiated mPDAC Phase 2 trial of onvansertib in combination with first-line SoC NALIRIFOX.
• The company will continue to enroll patients in the Phase 2 trial of onvansertib monotherapy in relapsed SCLC at the University of Maryland Greenebaum Comprehensive Cancer Center (UMGCCC).
• The company will continue to enroll patients in the Phase 1b/2 trial of onvansertib in combination with paclitaxel in patients with unresectable locally advanced or metastatic TNBC at Dana Farber Cancer Institute (DFCI).

Key Dates

Keywords

Onvansertib, PLK1 inhibitor, Colorectal cancer, Pancreatic cancer, Lung cancer, Breast cancer, Clinical trials, Biotechnology, Oncology, RAS-mutated, mCRC, mPDAC, SCLC, TNBC